Theresa Koppie, MD
Urology · Portland, ORNPI 1881794352
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,683 of the $3,026 with a category attached, or 88.7%. 35 manufacturers reported payments, led by Astellas Pharma US Inc at 28.0% of the total. Reporting peaked in 2023 at $1,272 and has fallen 98.3% since, to $22 in 2025.
Across 136 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$848
- Johnson & Johnson$362
- AbbVie$319
- Sumitomo Pharma America, Inc.$169
- Boston Scientific$156
- Dendreon Pharmaceuticals LLC$98
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,68389%
- Education$34311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 33 | $848 |
| Johnson & Johnson | 10 | $362 |
| AbbVie(2 entities) | 21 | $319 |
| Sumitomo Pharma America, Inc. | 7 | $169 |
| Boston Scientific | 10 | $156 |
| Dendreon Pharmaceuticals LLC | 4 | $98 |
| AstraZeneca | 3 | $89 |
| 180 Medical, Inc. | 3 | $88 |
| Pfizer | 5 | $88 |
| Bayer | 4 | $82 |
| Merck | 3 | $80 |
| Tolmar, Inc. | 4 | $64 |
| Amgen | 2 | $59 |
| Verity Pharmaceuticals Inc. | 3 | $58 |
| Coloplast | 3 | $51 |
| Sun Pharmaceutical Industries Inc. | 1 | $39 |
| Smith+Nephew | 1 | $32 |
| Accord Healthcare, Inc. | 1 | $30 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $27 |
| Ambu Inc. | 1 | $26 |
| Dornier Medtech America, Inc | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Novartis | 1 | $22 |
| Procept Biorobotics Corporation | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| EDAP Technomed Inc | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Tempus AI, Inc | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
| Cook Medical LLC | 1 | $13 |
| Convatec Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 2 | $8 |
How this compares
$3,026 in reported general payments places this provider in the 65th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 29 | $425,865 |
| MyrbetriqMirabegron | 128 | $81,990 |
| GemtesaVibegron | 100 | $72,375 |
| Methenamine Hippurate | 130 | $7,390 |
| Tamsulosin Hcl | 439 | $5,644 |
| Solifenacin Succinate | 103 | $3,119 |
| Finasteride | 191 | $1,680 |
| Oxybutynin Chloride ErOxybutynin Chloride | 48 | $1,267 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 57 | $1,235 |
| Cephalexin | 147 | $1,117 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 21 | $713 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $551 |
| Doxazosin Mesylate | 22 | $399 |
| Oxybutynin Chloride | 26 | $351 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $848 | $507,854157 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $169 | $72,375100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Sara Spettel AliyarPortland$21K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.